35739-70-9

Basic information

• Product Name: dimethyldichlorotitanium(IV)
• Synonyms: dimethyldichlorotitanium(IV)
• CAS NO: 35739-70-9
• Molecular Weight: 148.856
• Mol File: 35739-70-9.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: dimethyldichlorotitanium(IV)(CAS DataBase Reference)
• NIST Chemistry Reference: dimethyldichlorotitanium(IV)(35739-70-9)
• EPA Substance Registry System: dimethyldichlorotitanium(IV)(35739-70-9)

Safety Data

• Hazardous Substances Data: 35739-70-9(Hazardous Substances Data)

Upstream product

• 19289-17-9 TiCl₄*1,2-DME 
• 917-54-4 methyllithium 
• 7440-32-6 titanium 
• 74-87-3 methylene chloride 
• 7550-45-0 titanium tetrachloride 
• 544-97-8 dimethyl zinc(II) 

Downstream Products

• 1068-19-5 4,4-dimethyl-heptane 
• 21019-60-3 (Z)-4-methyl-3-hexen-1-ol 
• 63714-11-4 trans-4-methyl-3-hexen-1-ol 
• 58927-81-4 (+/-)-(4E)-4-hepten-2-ol 
• 33429-72-0 2-chloro-4,4-dimethylpentane 
• 106543-70-8 2,2,4,4,6,6,8,8-Octamethyl-3,7-dioxabicyclo<3.3.0>oct-1(5)-en 
• 54750-40-2 1-(1,2-dimethylcyclopent-2-en-1-yl)-4-methylbenzene 
• 16982-00-6 1-(1,2,2-trimethylcyclopentyl)-4-methylbenzene 
• 88764-87-8 (1S,1'R,3'R)-1-cyclohexyl-1-(3'-hydroxy-1'-methylbutoxy)ethane 
• 88726-10-7 (1R,1'R,3'R)-1-cyclohexyl-1-(3'-hydroxy-1'-methylbutoxy)ethane 
• 92849-06-4 1-chloro-3-(1-methylpentyl)benzene 
• 53628-87-8 2,2-Dicyclopropyl-propan 
• 76953-96-3 1-(4-methoxyphenyl)-1-(trifluoromethyl)ethanol 
• 5980-96-1 1-isopropyl-2,4,6-trimethylbenzene 

Relevant articles and documents

Catalytic asymmetric formal total synthesis of (+)-dichroanone and (+)-taiwaniaquinone H

Catalytic asymmetric formal total synthesis of (+)-dichroanone and (+)-taiwaniaquinone H has been achieved. Key step involved construction of all-carbon quaternary carbon by palladium-catalyzed conjugate addition of arylboronic acid to 3-methyl cyclohexenone. Furthermore, a new approach to build [6-5-6] tricyclic backbone via formyl introduction and subsequent aldol-type condensation was also explored.

Titanium Catalysts with Linked Indenyl-Amido Ligands for Hydroamination and Hydroaminoalkylation Reactions

Titanium complexes containing a bridging indenylethylamido ligand have been synthesized and used as catalysts for hydroamination and hydroaminoalkylation reactions. All dichloro titanium complexes (η5:η1-Ind-C2H4-NR)TiCl2 (R = i-Pr (2a), t-Bu (2b), Cy (2c), Ph (2d)), which were prepared by reacting TiCl4(Et2O)2 with Li2[Ind-C2H4-NR], were fully characterized by single-crystal X-ray analysis. Reaction of 2a-c with methyllithium gave the thermally sensitive corresponding dimethyl titanium complexes [η5:η1-Ind-C2H4-N(alkyl)]TiMe2 (alkyl = i-Pr (3a), t-Bu (3b), Cy (3c)), while the N-aryl-substituted dimethyl titanium complexes [η5:η1-Ind-C2H4-N(aryl)]TiMe2 (aryl = Ph (3d), p-MeOC6H4 (3e)) were directly prepared by reacting Li2[Ind-C2H4-N(aryl)] with in situ generated Cl2TiMe2. In the case of complex 3d, the molecular structure could be determined by single-crystal X-ray analysis. All dimethyl titanium complexes (η5:η1-Ind-C2H4-NR)TiMe2 (R = i-Pr (3a), t-Bu (3b), Cy (3c), Ph (3d), p-MeOC6H4 (3e)) were finally used as precatalysts for the intermolecular hydroaminoalkylation of 1-octene (4), the intramolecular hydroamination and hydroaminoalkylation reactions of aminoalkenes, and the intermolecular hydroamination of 1-phenylpropyne (12). These experiments showed that the N substituent of the indenylethylamido ligand strongly influences the activity of the catalysts in the individual reactions.

Substituted heterocyclylbenzylpyrazoles and use thereof

The present application relates to novel substituted 1-[3-(heterocyclyl)benzyl]-1H-pyrazole derivatives, to processes for preparation thereof, to use thereof for treatment and/or prevention of diseases and to use thereof for production of medicaments for treatment and/or prevention of diseases, more particularly for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be effected in the form of monotherapy or else in combination with other medicaments or further therapeutic measures.